Mary Ann Liebert, Inc. has announced the appointment of Professors Charles Nichols, PhD and Peter Hendricks, PhD as co-Editors-in-Chief of Psychedelic Medicine, a new peer-reviewed hybrid journal launching in early 2023.
Publishing online and in print with open access options, Psychedelic Medicine will provide an authoritative, high-profile forum for groundbreaking original research papers in both the basic and clinical sciences, review articles, debate, and commentary. A preview issue of the Journal is planned for late 2022.
Charles Nichols is a Professor of Pharmacology at LSU Health Sciences Center in New Orleans and has been researching psychedelics for 25 years. He received his PhD at Carnegie Mellon University studying the developmental genetics of fruit fly eye and retina development. He performed his postdoctoral work at Vanderbilt University School of Medicine in the Department of Pharmacology researching serotonin 5-HT2 receptor neuropharmacology and psychedelics under the mentorship of Dr. Elaine Sanders-Bush. Dr. Nichols’s research centers on the pharmacology of serotonin 5-HT2A receptors, and he and his laboratory have made several key discoveries throughout the years.
Professor Nichols is a founding member of the International Society for Research on Psychedelics (ISRP), and serves as the society’s current President-Elect, and North American Councilor for the International Society of Serotonin Research (ISSR).
Peter Hendricks is Professor and Director of Research in the Department of Health Behavior, School of Public Health, at the University of Alabama at Birmingham (UAB). A clinical psychologist by training, Dr. Hendricks received his PhD from the University of South Florida studying tobacco dependence and interventions for smoking cessation. He completed a postdoctoral fellowship on drug abuse treatment and services research at the University of California, San Francisco before joining UAB in 2010. Dr. Hendricks’ research centers on the development of novel and potentially more effective treatments for substance use disorders and comorbid conditions, with specific areas of focus on tobacco, cocaine, cannabis, opiate, and polysubstance dependence in vulnerable populations, including individuals in the criminal justice system. Dr. Hendricks is also site PI of a NIDA-funded study of psilocybin for smoking cessation.
Psychedelic Medicine will provide rapid, fair peer-review, and welcomes original research papers on every aspect of psychedelic medicine including basic science, clinical, and translational research, as well as medical applications.
Click here to read the original press release.
